Serological Assays for the Detection and Characterization of Influenza Viruses

SOL #: 0001Award Notice

Overview

Buyer

Health And Human Services
Centers For Disease Control And Prevention
CDC OFFICE OF ACQUISITION SERVICES
ATLANTA, GA, 30333, United States

Place of Performance

Atlanta, GA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

Reference Laboratory Testing (Q301)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 9, 2026
2
Last Updated
May 18, 2026

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Centers for Disease Control and Prevention (CDC), specifically the Influenza Division, is soliciting proposals for Serological Assays for the Detection and Characterization of Influenza Viruses. The objective is to support the Influenza Division through the testing of human sera via hemagglutination inhibition (HAI) assay and to develop a new serology platform comparable to HAI. Proposals are due by 2:00 PM local time on February 24, 2026.

Scope of Work

  • Core Requirement: Perform HAI serological assays on human samples, with an approximate base level of 6,000 samples per year. Additional surge options (50% and 75% above base) may be exercised.
  • Optional Task 1: Conduct a gap analysis for developing a new serology assay.
  • Optional Task 2: Develop a new serology assay comparable to HAI.
  • Key Deliverables: HAI assay protocols, proficiency panel reports, sample testing results, interim and final technical summary reports, annual reports, and a technical proposal for optional tasks.
  • Government Furnished Materials: Protocols for serological testing, antiserum, viruses/antigens, proficiency panels, and human samples will be provided.

Contract & Timeline

  • Contract Type: Firm-Fixed-Price (FFP) for core requirements, with a Cost-Plus-Fixed-Fee (CPFF) completion for optional tasks.
  • Period of Performance: A base period from May 19, 2026, to May 18, 2027, followed by four 12-month option periods, extending through May 18, 2031.
  • Total Contract Value: $7,335,701.00.
  • NAICS Code: 325413 (In-Vitro Diagnostic Substance Manufacturing) with a small business size standard of 1,250 employees.
  • Proposal Due: February 24, 2026, at 2:00 PM local time.
  • Published: May 18, 2026.

Evaluation

  • The solicitation references "Evaluation Factors for Award" but does not detail them in the provided summary.
  • This acquisition is competed under FAR Part 15 - Contracting by Negotiation.

Additional Notes

  • This is a performance-based, non-personal services contract.
  • The Service Contract Act applies.
  • Travel will be reimbursed at actual cost.
  • Electronic and Information Technology (EIT) accessibility standards are applicable.
  • Contractor performance will be evaluated using the Contractor Performance Assessment Reporting System (CPARS).

People

Points of Contact

Jennifer GartzkePRIMARY
jgartzke@cdc.gov

Files

Files

Download

Versions

Version 2Viewing
Award Notice
Posted: May 18, 2026
Version 1
Award Notice
Posted: Apr 9, 2026
View